MEDI 6469

Drug Profile

MEDI 6469

Alternative Names: Anti-OX40 monoclonal antibody; MEDI-6469

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AgonOx; Providence Cancer Center
  • Developer MedImmune; Providence Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Diffuse large B cell lymphoma; Prostate cancer; Solid tumours
  • Phase I Colorectal cancer; Head and neck cancer

Most Recent Events

  • 27 Mar 2017 MedImmune terminates early a phase I/II trial in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Second-line therapy or greater) and Diffuse large B cell lymphoma (Combination therapy, Monotehrapy, Late-stage disease) in USA at the sponsor's discretion (IV) (NCT02205333)
  • 16 Dec 2016 Biomarkers information updated
  • 01 Apr 2016 MedImmune completes a phase I/II trial in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Second-line therapy or greater) and Diffuse large B cell lymphoma (Combination therapy, Monotehrapy, Late-stage disease) in USA (IV) (NCT02205333)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top